Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 113Colonic Neoplasms 30Neoplasm Metastasis 28Rectal Neoplasms 27Neoplasms 27Carcinoma, Non-Small-Cell Lung 14Esophageal Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Pancreatic Neoplasms 9Head and Neck Neoplasms 9Lung Neoplasms 8Cholangiocarcinoma 7Carcinoma, Squamous Cell 6Breast Neoplasms 6Colorectal Cancer Metastatic 5Carcinoma 5Triple Negative Breast Neoplasms 4Recurrence 4Prostatic Neoplasms 4Ovarian Neoplasms 4Inflammatory Breast Neoplasms 3Gastrointestinal Neoplasms 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Kidney Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2

Interventions

Gemcitabine 92Cisplatin 70Oxaliplatin 37Capecitabine 37durvalumab 29Fluorouracil 26pembrolizumab 24Leucovorin 22S 1 (combination) 18Nivolumab 13Irinotecan 13Bevacizumab 13lenvatinib 12tremelimumab 10apatinib 8Trastuzumab 7Injections 7Albumin-Bound Paclitaxel 7130-nm albumin-bound paclitaxel 7Paclitaxel 6Immune Checkpoint Inhibitors 6Docetaxel 6titanium silicide 5surufatinib 5envafolimab 5camrelizumab 5atezolizumab 5Folfox protocol 5Drug Therapy 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Biliary Tract Neoplasms × Panitumumab × Clear all
NCT00948935 2020-03-11

Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
35 enrolled 7 charts
Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT01308840 2016-08-17

UGIH09067

University of Rochester

Phase 2 Completed
31 enrolled 10 charts
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡